Cargando…
Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril–valsartan in Heart Failure with Reduced Ejection Fraction
BACKGROUND: Recent studies have demonstrated that angiotensin receptor neprilysin inhibitors (ARNIs) can reverse the cardiac remodeling effects that occur in heart failure with reduced ejection fraction (HFrEF). These studies have also suggested that ARNIs have favorable effects on ventricular dyssy...
Autores principales: | Kim, Bong-Joon, Park, Han-Su, Im, Sung-Il, Kim, Hyun-Su, Heo, Jung-Ho, Cha, Tae-Joon, Cho, Kyoung-Im |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Echocardiography
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572265/ https://www.ncbi.nlm.nih.gov/pubmed/33086439 http://dx.doi.org/10.4250/jcvi.2020.0025 |
Ejemplares similares
-
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019) -
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018) -
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018) -
ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)